Efficacy of phase 1 trials in malignant pleural mesothelioma: Description of a series of patients at a single institution

Including MPM patients in phase I trials beyond first line of treatment can result in modest clinical benefits with an acceptable toxicity profile. Several molecular pathways involved in MPM have been identified and further novel biologic therapies need to be tested.